CA2106821A1 - Glycosylated cytokines - Google Patents

Glycosylated cytokines

Info

Publication number
CA2106821A1
CA2106821A1 CA002106821A CA2106821A CA2106821A1 CA 2106821 A1 CA2106821 A1 CA 2106821A1 CA 002106821 A CA002106821 A CA 002106821A CA 2106821 A CA2106821 A CA 2106821A CA 2106821 A1 CA2106821 A1 CA 2106821A1
Authority
CA
Canada
Prior art keywords
cytokine
sugar
modified
interferon
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002106821A
Other languages
English (en)
French (fr)
Inventor
Naoru Hamaguchi
Jun Sato
Kazuhiro Doken
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2106821A1 publication Critical patent/CA2106821A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CA002106821A 1992-09-24 1993-09-23 Glycosylated cytokines Abandoned CA2106821A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP254962/1992 1992-09-24
JP25496292 1992-09-24
JP088920/1993 1993-04-15
JP8892093 1993-04-15

Publications (1)

Publication Number Publication Date
CA2106821A1 true CA2106821A1 (en) 1994-03-25

Family

ID=26430256

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002106821A Abandoned CA2106821A1 (en) 1992-09-24 1993-09-23 Glycosylated cytokines

Country Status (9)

Country Link
US (1) US5643564A (cg-RX-API-DMAC10.html)
EP (1) EP0589378B1 (cg-RX-API-DMAC10.html)
KR (1) KR940007058A (cg-RX-API-DMAC10.html)
CN (1) CN1087916A (cg-RX-API-DMAC10.html)
AT (1) ATE229981T1 (cg-RX-API-DMAC10.html)
CA (1) CA2106821A1 (cg-RX-API-DMAC10.html)
DE (1) DE69332576T2 (cg-RX-API-DMAC10.html)
PH (1) PH31582A (cg-RX-API-DMAC10.html)
TW (1) TW263437B (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0770195A (ja) * 1993-08-23 1995-03-14 Yutaka Mizushima 糖修飾インターフェロン
IL116730A0 (en) * 1995-01-13 1996-05-14 Amgen Inc Chemically modified interferon
WO1997007820A1 (fr) * 1995-08-30 1997-03-06 Toray Industries, Inc. Remede destine aux maladies cardiaques
AUPP660698A0 (en) * 1998-10-21 1998-11-12 University Of Queensland, The A method of protein engineering
AR078117A1 (es) 2006-06-20 2011-10-19 Protech Pharma S A Una muteina recombinante del interferon alfa humano glicosilado, un gen que codifica para dicha muteina, un metodo de produccion de dicho gen, un metodo para obtener una celula eucariota productora de dicha muteina, un metodo para producir dicha muteina, un procedimiento para purificar dicha muteina
AU2012223210B2 (en) * 2011-03-02 2016-12-22 Board Of Regents Of The University Of Texas System Vesicle compositions
EP3129493B1 (en) 2014-04-09 2021-07-07 The Scripps Research Institute Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters
TWI821192B (zh) 2017-07-11 2023-11-11 美商新索思股份有限公司 非天然核苷酸之導入及其方法
IL321812A (en) 2017-08-03 2025-08-01 Synthorx Inc Cytokine complexes for the treatment of autoimmune diseases
MA54952A (fr) 2019-02-06 2022-05-11 Synthorx Inc Conjugués d'il-2 et méthodes d'utilisation de ceux-ci

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4386026A (en) * 1981-04-20 1983-05-31 Merck & Co., Inc. Cell-specific glycopeptide ligands
US4609546A (en) * 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
JP2514950B2 (ja) * 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質,その製造法および中間体
JPS63152393A (ja) * 1986-07-03 1988-06-24 Takeda Chem Ind Ltd グリコシル誘導体
HU206890B (en) * 1986-10-13 1993-01-28 Sandoz Ag Process for producing sugar-modified somatostatin peptide derivatives and pharmaceutical compositions containing them as active components
US5162503A (en) * 1987-05-19 1992-11-10 Hoffmann-La Roche, Inc. Purification of interleukin-2 by receptor-affinity chromatography
US4829690A (en) * 1987-06-26 1989-05-16 Andros Theodore A Credit card chain holder
JPH01102098A (ja) * 1987-10-14 1989-04-19 Toray Ind Inc 糖鎖修飾糖タンパク質
JPH01102099A (ja) * 1987-10-14 1989-04-19 Toray Ind Inc 生理活性を有する糖タンパク質
US4902502A (en) * 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
JPH03106900A (ja) * 1989-09-20 1991-05-07 Toray Ind Inc 糖鎖修飾ヒトインターフェロン集合体
JPH085914B2 (ja) * 1990-02-16 1996-01-24 株式会社ディ・ディ・エス研究所 グリコシル−蛋白誘導体
US5096816A (en) * 1990-06-05 1992-03-17 Cetus Corporation In vitro management of ammonia's effect on glycosylation of cell products through pH control
JPH0770195A (ja) * 1993-08-23 1995-03-14 Yutaka Mizushima 糖修飾インターフェロン

Also Published As

Publication number Publication date
ATE229981T1 (de) 2003-01-15
EP0589378B1 (en) 2002-12-18
US5643564A (en) 1997-07-01
PH31582A (en) 1998-11-03
CN1087916A (zh) 1994-06-15
EP0589378A2 (en) 1994-03-30
DE69332576T2 (de) 2003-11-20
TW263437B (cg-RX-API-DMAC10.html) 1995-11-21
EP0589378A3 (en) 1995-02-22
KR940007058A (ko) 1994-04-26
DE69332576D1 (de) 2003-01-30

Similar Documents

Publication Publication Date Title
ES2214551T3 (es) Terapia de infusion continua de citocinas a baja dosis.
US5723121A (en) Sugar modified interferon
Bautista Chronic alcohol intoxication induces hepatic injury through enhanced macrophage inflammatory protein‐2 production and intercellular adhesion molecule‐1 expression in the liver
US6719969B1 (en) Treatment of liver disease and injury with CXC chemokines
AU2003286624B2 (en) Methods for treating viral infection using IL-28 and IL-29
CZ247194A3 (en) Conventional leukocytic interferon, its use for preparing a medicament and a pharmaceutical preparation based thereon
Butler et al. Interleukin 1-induced pathophysiology: induction of cytokines, development of histopathologic changes, and immunopharmacologic intervention
SK149199A3 (en) Polyethylene glycol-interferon alpha conjugates for therapy of infection
ZA200102917B (en) Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection.
US5643564A (en) Glycosylated cytokines
EP1599171A2 (en) Combination therapy for treating alphavirus infection and liver fibrosis
JPH10513440A (ja) 化学的に修飾したインターフェロン
Chadha et al. Interferons and interferon inhibitory activity in disease and therapy
IE913656A1 (en) Methods and compositions for the treatment of cell¹proliferation disorders
BRPI0622128A2 (pt) conjugado de polietileno glicol-g-csf
Manthey et al. Role of Kupffer cells in developing streptococcal cell wall granulomas. Streptococcal cell wall induction of inflammatory cytokines and mediators
JP4414494B2 (ja) 白血球減少症の予防剤および治療剤
WO2001010899A2 (en) Treatment of liver disease and injury with cxc chemokines
JPH05255106A (ja) 血小板減少症治療剤
JPH06345795A (ja) 糖修飾サイトカイン
BRPI0621664A2 (pt) conjugado de interferon alfa com polietileno glicol
JPH11222440A5 (cg-RX-API-DMAC10.html)
KR20010024044A (ko) 만성씨형간염의치료에서동시적으로,개별적으로또는연속적으로사용하기위한,아이에프엔-알파와아만타딘이조합되어사용되는약제
MXPA97005119A (en) Modified interferone quimicame
JPH06247873A (ja) 肝実質細胞増殖因子の誘導剤

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued